Summary

Overview
Global Bone Cancer Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Bone cancer is characterized by the uncontrolled growth of cells in the bone. Different types of bone tissue give rise to different types of primary bone cancer. Osteosarcoma develops from cells that form the bone, and Ewing sarcoma develops from immature nerve tissue within the bone. Bone cancer is rare which makes up less than 1 percent of all cancers and commonly affects the pelvis or the long bones in the arms and legs.
The global bone cancer market has witnessed significant growth in recent years due to the adoption of immunotherapy techniques such as CAR T-cell therapy for bone cancers. For instance, B7-H3-targeted CAR-T cells can eradicate ewing sarcoma xenografts in vivo which leads to significant survival advantages.
Furthermore, significant growth drivers such as increasing product approvals, investments for bone cancer treatment, and research and developments give rise to future market growth. Significant key players like Eli Lilly and Company, Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., and others are actively operating in the market.
Market Dynamics
Increasing research and developments for bone cancers
The global bone cancer treatment market has witnessed significant growth due to various recent research and developments. Bone cancer is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating major bone cancers help to accelerate market growth.
For instance, in March 2023, researchers at the University of East Anglia developed a new drug that works against all of the main types of primary bone cancer. This new drug called ‘CADD522’ blocks a gene associated with driving cancer’s spread and increases survival rates by 50 percent without the need for surgery or chemotherapy.
Additionally, according to the National Institue of Health, an article entitled Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma published in January 2022 states that recent studies showed several biomarkers and therapeutic targets for chondrosarcoma including IDH1/2, COL2A1, and PD-L1. In addition, several molecule-targeting agents and immunotherapy have shown favorable antitumor activities in clinical studies of patients with advanced chondrosarcoma.
Increasing investments for bone cancer treatment
Bone cancer occurs when a tumor, or atypical mass of tissue forms in a bone, and the tumor can be malignant or benign in nature. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new treatments for bone cancers.
For instance, in August 2023, Zetagen Therapeutics secured a 9.79 Million USD Series B Funding raise for the advancement of ZetaMet and ZetaMAST for the treatment of metastatic bone cancers and soft tissue tumors. ZetaMet is the first molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.
Additionally, according to an amended registration statement 2021, Inhibrx (INBX) has filed to raise $102 million from the sale of its common stock. The company is currently developing a range of potential treatments for rare types of cancer such as chondrosarcoma and mesothelioma, as well as other forms of cancer. Thus, owing to the above factors the market is expected to boost over the forecast period.
Aftereffects associated with chemotherapy are expected to hamper global bone cancer treatment market
Chemotherapy is a widely used cancer treatment that involves the use of drugs to destroy or slow the growth of tumor cells. Although, chemotherapy also affects healthy cells in the body which leads to various side effects.
For instance, the Leukemia Foundation states that chemotherapy can harm fast-growing normal cells, such as hair cells and cells that make up tissues in the mouth, gut, and bone marrow. Additionally, chemotherapy can impact the bone marrow's capability to generate sufficient amounts of blood cells, leading to a decrease in blood count within a week of treatment. Hence, owing to the above factors, the market is expected to hamper over the forecast period.
For more details on this report – Request for Sample
Segment Analysis
The global bone cancer treatment market is segmented based on type, treatment, end users, and region.
Chemotherapy from the treatment segment accounted for approximately XX% of the global bone cancer treatment market share
Chemotherapy is commonly used for the treatment of various cancers including bone cancers by using anti-cancer drugs to destroy the bone tumor cells. Chemotherapy is expected to hold the largest market share over the period forecast owing to increasing clinical trials conducted for bone cancers with chemotherapy treatment drugs. A total of 446 clinical trials were performed for the treatment of bone cancers with chemotherapy drugs.
For instance, according to clinicalTrials.gov, on July 3, 2023, the School of Medicine, Zhejiang University conducted a clinical trial on the Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma. This study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.
Additionally, on December 9, 2022, UNICANCER conducted a clinical trial on Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High-Risk Osteosarcoma Patients. The study aims to evaluate the impact on the efficacy of mifamurtide as an add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma.
Geographical Penetration
North America accounted for approximately 38.4% of the market share in 2022
The global bone cancer treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the bone cancer treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of bone cancers, FDA approvals, and research and developments in bone cancer treatment.
For instance, the American Cancer Society’s estimation for primary cancer of the bones and joints for 2023 is about 3,970 new cases diagnosed (2,160 in males; 1, 810 in females) and around 2,140 deaths in the United States.
In April 2023, Sumitomo Pharma Oncology, Inc. received an FDA orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma. TP-1287 exhibits potent inhibition of intracellular kinases including CDK9. Inhibition of CDK9 leads to downregulation of key antiapoptotic proteins such as MCL-1, which in turn has been shown to inhibit tumor growth.
Competitive Landscape
The major global players in the market include Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., Cipla Ltd., Aspen API Inc., Eli Lilly and Company, Gatewell Oncology Pvt. Ltd., Recordati Rare Diseases Inc., Novartis AG among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global bone cancer treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in bone cancer treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the bone cancer treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the bone cancer treatment market is expected to be moderately affected over the forecast period.
By Type
• Primary Bone Cancer
o Osteosarcoma
o Chondrosarcoma
o Ewing Sarcoma
o Chordoma
• Secondary Bone Cancer
o Bone Metastasis
By Treatment
• Surgery
• Chemotherapy
o Doxorubicin
o Cisplatin
o Etoposide
o Vincristine
• Radiation Therapy
o Proton-Beam Radiation Therapy
o Stereotactic Radiosurgery
o Intensity-Modulated Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Others
By End Users
• Hospitals
• Oncology Centers
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In July 2023, a Korean drug developer, MedPacto’s drug vactosertib received the European Medicines Agency (EMA’s) orphan drug designation for the treatment of osteosarcoma.
• In August 2022, Inhibrx Inc. declared that the European Commission has granted an orphan medicinal product designation to INBRX-109 for use as a potential therapeutic option in patients with chondrosarcoma. The drug is based on a single-domain antibody platform which comprises 2 identical camelid heavy chain-only antibody-binding domains targeting DR5.
Why Purchase the Report?
• To visualize the global bone cancer treatment market segmentation based on type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global bone cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global bone cancer treatment market report would provide approximately 61 tables, 60 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents